TANABE MITSUBISHI PHARMA CORPORATION, a subsidiary of MITSUBISHI CHEMICAL, has signed an agreement to transfer the selective anti-thrombin drug "argatroban hydrate" business in Europe to Ethypharm (France, Paris, CEO: Denis Delval, hereinafter referred to as "Ethypharm "). In the European business of Tanabe Mitsubishi Pharma, we have decided to transfer the argatroban business to Ethypharm under the policy of focusing on ALS therapeutic drug "Radicava" with the generic name of edaravone. In Europe, Mitsubishi Tanabe Pharma Europe Ltd., a subsidiary of Tanabe Mitsubishi Pharma, and Mitsubishi Tanabe Pharma GmBH, a subsidiary of MTPE, which is engaged in sales of argatroban in the United Kingdom, Germany, and other European countries through partner companies. Ethypharm has strengths in the central nervous system (CNS) disease area and injection drugs. Through the succession of Tanabe Mitsubishi Pharma's European argatroban business, we aim to further strengthen the pharmaceutical business and contribute to the medical needs of various European countries through the provision of argatroban. Tanabe Mitsubishi Pharma will continue to contribute to European patients by providing medicines including Radicava through MTPE and MTPD. Argatroban is a selective anti-thrombin drug developed by Tanabe Mitsubishi Pharma, and is sold in Japan under the name "Novastan HI Injection." In Europe, since its approval in Sweden in 2004, it has been sold as a therapeutic drug for "heparin-induced thrombocytopenia (HIT) type II" in 13 countries, including Germany, the United Kingdom, France, Spain, and Italy.

In the European business of Tanabe Mitsubishi Pharma, we have decided to transfer the argatroban business to Ethypharm under the policy of focusing on ALS therapeutic drug "Radicava" with the generic name of edaravone.^{® Please use your Futubull account to access the feature.}Under the policy of focusing on the Edaravone (generic name: Edaravone) business, the Argatroban business will be transferred to Ethypharm.

In Europe, Mitsubishi Tanabe Pharma Europe Ltd., a subsidiary of Tanabe Mitsubishi Pharma, and Mitsubishi Tanabe Pharma GmBH, a subsidiary of MTPE, which is engaged in sales of argatroban in the United Kingdom, Germany, and other European countries through partner companies.

Ethypharm has strengths in the central nervous system (CNS) disease area and injection drugs. Through the succession of Tanabe Mitsubishi Pharma's European argatroban business, we aim to further strengthen the pharmaceutical business and contribute to the medical needs of various European countries through the provision of argatroban.

Tanabe Mitsubishi Pharma will continue to contribute to European patients by providing medicines including Radicava through MTPE and MTPD.^{® Please use your Futubull account to access the feature.}We will continue to contribute to the European patients by providing pharmaceuticals, including pharmaceuticals.

Argatroban is a selective anti-thrombin drug developed by Tanabe Mitsubishi Pharma, and is sold in Japan under the name "Novastan HI Injection." In Europe, since its approval in Sweden in 2004, it has been sold as a therapeutic drug for "heparin-induced thrombocytopenia (HIT) type II" in 13 countries, including Germany, the United Kingdom, France, Spain, and Italy.
"Heparin-induced thrombocytopenia (HIT) type II" is a severe disease that may cause lethal thromboembolism. Argatroban is an anticoagulant suitable for patients who developed HIT type II before and after surgery, and patients with renal disease because its half-life in blood is short and it is metabolized in the liver.

Ethypharm is a mid-sized international pharmaceutical company based in Europe, engaged in manufacturing and selling medical drugs, mainly for hospitals, central nervous system (severe pain and addiction), and general medicine. It promises to improve patients' lives and have a positive impact on society and the environment. Ethypharm has 1,700 employees who engage in various pharmaceutical-related businesses, with 1,400 of them engaged in industrial activities. Its six manufacturing facilities in France, the United Kingdom, Spain, and China have expertise in injection drugs and complex oral solid formulations.

News for 2024